Radiotherapy clinical trials at UCSF
1 research study open to eligible people
Radiotherapy is a method that uses radiation to treat diseases like cancer. UCSF is conducting trials to study NBTXR3, activated by radiotherapy, to explore enhanced effects when combined with an anti-PD-1 treatment. These trials aim to determine optimal dosing for advanced cancer patients.
Showing trials for
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
open to eligible people ages 18 years and up
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
San Francisco, California and other locations
Our lead scientists for Radiotherapy research studies include Jason Chan.
Last updated: